SciClone Pharmaceuticals (SCLN) Shares are Down -0.76%

SciClone Pharmaceuticals (SCLN) : During the past 4 weeks, traders have been relatively bearish on SciClone Pharmaceuticals (SCLN), hence the stock is down -22.47% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -0.82% relative to the S&P 500. The 4-week change in the price of the stock is -21.67% and the stock has fallen -0.76% in the past 1 week.

The stock has recorded a 20-day Moving Average of 3.38% and the 50-Day Moving Average is 16.4%. SciClone Pharmaceuticals (NASDAQ:SCLN): On Fridays trading session , Opening price of the stock was $10.58 with an intraday high of $10.64. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $10.23. However, the stock managed to close at $10.41, a loss of 2.35% for the day. On the previous day, the stock had closed at $10.66. The total traded volume of the day was 632,315 shares.


The company Insiders own 6.95% of SciClone Pharmaceuticals shares according to the proxy statements. Institutional Investors own 80.1% of SciClone Pharmaceuticals shares.

SciClone Pharmaceuticals Inc. (SciClone) is a pharmaceutical company. The Company operates in two geographic segments, including China and the rest of the world (the United States and Hong Kong). The Companys lead product ZADAXIN (thymalfasin) is used for the treatment of hepatitis B virus (HBV) hepatitis C (HCV) as a vaccine adjuvant and certain cancers. Its development portfolio includes Angiomax, an anticoagulant indicated in patients undergoing percutaneous coronary intervention (PCI); Neucardin, therapeutic drug for the treatment of patients with intermediate to advanced chronic heart failure (CHF); Loramyc, a mucoadhesive tablet formulation of miconazole lauriad to treat oropharyngeal candidiasis; Cleviprex, a third-generation dihydropyridine calcium channel blocker for the reduction of blood pressure; ProFlow to treat peripheral arterial disease (PAD) and other indications, and RapidFilm, an oral film formulation of ondansetron to treat nausea induced by chemotherapy.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.